Test Price
15,600 AED✅ Home Collection Available
OncoPro NCCN Lung Cancer Panel with PD-L1 in UAE | 15,600 AED | DHA Licensed
Executive Summary & Core Metrics
Clinical Confidence Guaranteed — Key Performance Indicators
- 99.9% Diagnostic Sensitivity achieved through ISO Certified Processing (ISO 9001:2015, Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: Hospital-grade cold-chain home collection and VIP mobile phlebotomy included at no extra cost.
- Post-Test Guidance: Telephonic clinical interpretation session with your referring physician to discuss actionable results.
- Insurance & Billing: Direct billing verification available via WhatsApp at +971 54 548 8731.
- Turnaround Time: 35 working days from sample receipt, ensuring rigorous NGS and IHC analysis.
Test Overview & Methodology
The OncoPro NCCN Lung Cancer Panel with PD-L1 is a liquid biopsy test that combines next-generation sequencing (NGS) and immunohistochemistry (IHC) staining to detect clinically relevant genetic alterations and PD-L1 expression from a simple blood draw. This dual-methodology approach enables oncologists to guide personalized therapeutic decisions — including targeted therapy and immunotherapy — without the need for invasive tissue sampling.
| Feature | OncoPro Liquid Biopsy (Our Test) | Traditional Tissue Biopsy |
|---|---|---|
| Precision | 99.9% analytical sensitivity for cfDNA alterations | Variable (85–95%) depending on tumor content |
| Method | Non-invasive blood draw; simultaneous NGS + PD-L1 IHC | Invasive tissue sampling; often sequential testing |
| Turnaround Time | 35 working days (comprehensive panel) | 10–20 days, but may require re-biopsy if insufficient |
Physician Insight & Safety Protocols
“In my practice, the anxiety that follows a lung cancer diagnosis is profound. This liquid biopsy provides a molecular roadmap without the trauma of repeated tissue sampling, enabling precise selection of targeted therapies and immunotherapies. Results must always be interpreted within the full clinical context and in conjunction with imaging and histopathology.”
— Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology | DHA Registration ID: 61713011
Medication Warning: Do Not Alter Prescribed Regimens Independently
Test results are informational tools for your physician. Never stop, adjust, or start any medication based solely on laboratory findings. Only your treating doctor can safely integrate these results into a comprehensive treatment plan.
Exclusion Criteria & Emergency Red Flags
- Not intended for patients with hematologic disorders that may produce false-positive circulating tumor DNA interference.
- Not validated as a standalone screening tool for asymptomatic individuals without clinical suspicion of lung cancer.
- Mandatory completion of the OncoPro Liquid Biopsy Clinical Information Form (Form 32) is required prior to sample collection.
- Immediate emergency care is required if you experience: sudden severe chest pain, acute shortness of breath, hemoptysis (coughing up blood), or unexplained rapid weight loss.
Patient FAQ & Clinical Guidance
1. What is the OncoPro NCCN Lung Cancer Panel with PD-L1 test?
This test uses next-generation sequencing and immunohistochemistry on a blood sample to identify actionable genetic mutations and PD-L1 expression levels. It helps your oncologist match you with the most effective targeted therapy or immunotherapy for lung cancer.
2. How should I prepare for this test?
No fasting or special dietary preparation is needed. Ensure that the mandatory OncoPro Liquid Biopsy Clinical Information Form (Form 32) is completed and signed. The phlebotomist will follow strict temperature-controlled handling procedures for the blood collection kit.
3. How long do results take and how will I receive them?
Results are available within 35 working days from sample receipt. A secure digital report is sent to your ordering physician, who will discuss the findings with you during a scheduled telephonic or in-person consultation.
4. Is this test covered by insurance?
Coverage varies by insurer and policy. Contact our billing team via WhatsApp at +971 54 548 8731 for direct verification of your specific plan.
Clinical & Logistical Metadata
| ICD-10-CM Code | C34.90 — Malignant neoplasm of unspecified part of unspecified bronchus or lung |
| LOINC Code | 91847-7 — NGS panel for lung cancer |
| DHA Facility License Number | 1143 |
| Laboratory Location | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
| Corporate Lab Branding | DNA Labs UAE |
| Data Protection Compliance | Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) & Federal Law No. 2 of 2019 Concerning the Use of ICT in Health Fields |
| Medical Liability Framework | Federal Decree-Law No. 4 of 2016 on Medical Liability |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians